{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"80.3","upperLimit":"93.2","value":"86.8"},{"groupId":"OG001","lowerLimit":"77.9","upperLimit":"91.6","value":"84.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"ORR: percentage of participants who achieved best overall response of either CR, CRi, nodular PR (nPR) and partial response (PR). iWCLL 2008 criteria: CR- No lymphadenopathy and hepatosplenomegaly, no constitutional symptoms, neutrophils \\>1.5\\*10\\^9/liter (L), platelets \\>100\\*10\\^9/L, Hgb \\>11 g/dL and ALC \\<4000/mcL, normocellular bone marrow with \\<30% lymphocytes and no B lymphoid nodules; CRi- CR with incomplete recovery of bone marrow; nPR- participants meet criteria for CR, but bone marrow biopsy shows B-lymphoid nodules (reflecting residual disease); PR-2 of following when abnormal at baseline: \\>=50% decrease in ALC, \\>=50% decrease in sum of products of multiple nodes, \\>=50% decrease in enlargement of spleen or liver; and 1 of following: neutrophils \\>1.5\\*10\\^9/L, Platelets \\>100\\*10\\^9/L and Hgb\\>11 g/dL or \\>=50% improvement over baseline in any of these; 50% reduction in bone marrow infiltrates or B lymphoid nodules; no new enlarged nodes or new hepatosplenomegaly.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received ibrutinib 420 milligrams (mg) orally once daily for 3 cycles (each cycle is of 28 days) followed by the combination of ibrutinib 420 mg and venetoclax 400 mg orally once daily for 12 cycles (including a 5-week venetoclax dose ramp up starting in cycle 4). Participants who subsequently developed independent review committee (IRC)-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment Arm A (Ibrutinib + Venetoclax)"},{"description":"Participants received chlorambucil 0.5 milligrams per kilogram (mg/kg) body weight orally once daily on Days 1 and 15 of Cycles 1 to 6 in combination with obinutuzumab 1000 mgs intravenously (IV) once daily on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 to 6 (each cycle is of 28 days). Participants who subsequently developed IRC-confirmed progressive disease (PD) and had active disease requiring treatment were eligible to participate in the Subsequent Therapy Phase and received single-agent ibrutinib until disease progression or unacceptable toxicity.","id":"OG001","title":"Treatment Arm B (Chlorambucil + Obinutuzumab)"}],"paramType":"NUMBER","populationDescription":"The ITT analysis set included all randomized participants who were analyzed according to assigned treatment group, regardless of the actual treatment received. Participants with missing post-randomization data were considered non-responders.","reportingStatus":"POSTED","timeFrame":"Up to 2 years 10 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}